Andy has experience in developing processes for the manufacture of biotechnology and fine chemical products. He has managed a department of 50 people responsible for the development of new human vaccines. He has a detailed knowledge of technologies such as fermentation, cell culture, separation, purification and chemical synthesis. His knowledge has been applied to products such as recombinant proteins, vaccines, biologicals, enzymes and fine c

Tracy has worked in senior capacities for seven start-ups including LifeScan (sold to Johnson and Johnson), BioTrak (sold to Roche) and Cholestech, recently acquired by Alear). He held senior management positions in the merger and acquisition business of the $1.7 billion life sciences division of Agilent Technologies (formerlY Hewlett-Packard) and GeneChip manufacturer, Affymetrix and has developed international sales and marketing organisations.

Bernd is professor of microbiology at Massey University and the inventor of the PolyBatics technology. Bernd is the author of over 100 papers on biopolymer production and is named on more then 10 patents. He is a recognized world authority on biopolymer production and is an editorial board member on eight scientific journals

Brad Duft is the President and CEO of CoDa Therapeutics, a New Zealand drug company. In addition to his role with CoDa, Brad is a US patent attorney and former general counsel at Amylin Therapeutics with experience in international patent and corporate law.

Jim is Charman of CoDa Therapeutics and a US attorney. Jim brings extensive experience in transactional and securities law. In addition to his role woth CoDa, Jim advises UniServices at Auckland University and is the founder of Barrier Therapeutics.

Dr. Garlend is the former Managing Director of New Zealand Pharmaceuticals. Richard oversaw the management buyout of NZP and ran the organization for many years. He brings experience in international markets and manufacturing.